How Nextech-led round will help Vividion to POC

$82M B round to advance small molecules from proteome-wide drug discovery platform

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest.

Now flush with over $165 million in cash, Vividion Therapeutics Inc. CEO Diego Miralles said the company will be able

Read the full 506 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE